Havemeyer Place LP Purchases New Shares in Becton, Dickinson and Company $BDX

Havemeyer Place LP purchased a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) during the 4th quarter, Holdings Channel reports. The fund purchased 5,657 shares of the medical instruments supplier’s stock, valued at approximately $1,098,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Imprint Wealth LLC purchased a new stake in Becton, Dickinson and Company during the 3rd quarter valued at $25,000. Steph & Co. raised its holdings in Becton, Dickinson and Company by 95.6% during the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock valued at $26,000 after buying an additional 65 shares during the period. WPG Advisers LLC increased its stake in Becton, Dickinson and Company by 64.2% in the fourth quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 61 shares during the period. Accredited Wealth Management LLC increased its stake in Becton, Dickinson and Company by 77.8% in the third quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 70 shares during the period. Finally, Kohmann Bosshard Financial Services LLC purchased a new stake in Becton, Dickinson and Company in the fourth quarter worth $32,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Activity

In other news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the transaction, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. This represents a 2.45% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 2,913 shares of company stock worth $426,806. 0.40% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Price Performance

BDX opened at $151.33 on Monday. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The business’s fifty day simple moving average is $150.72 and its 200-day simple moving average is $175.43. The company has a market capitalization of $41.70 billion, a price-to-earnings ratio of 38.31, a PEG ratio of 10.70 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The business had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.67 billion. During the same quarter in the prior year, the company earned $3.35 EPS. The business’s revenue was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, equities research analysts anticipate that Becton, Dickinson and Company will post 12.61 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be given a dividend of $1.05 per share. The ex-dividend date of this dividend is Tuesday, June 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.8%. Becton, Dickinson and Company’s dividend payout ratio is presently 106.33%.

Analyst Ratings Changes

A number of research firms have weighed in on BDX. Argus reduced their target price on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating on the stock in a research note on Monday, March 23rd. Stifel Nicolaus reduced their target price on Becton, Dickinson and Company from $215.00 to $175.00 in a research note on Thursday, May 7th. The Goldman Sachs Group reduced their target price on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 27th. Zacks Research upgraded Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research note on Friday, April 10th. Finally, Piper Sandler reduced their target price on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a research note on Friday, April 17th. Seven equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $183.64.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.